AI Research Rounds: BRAF Gene in Ameloblastoma — Molecular Biology and Differential Treatment Strategies
Research Date: 2026-05-17
Research Question: What is the role of the BRAF gene in ameloblastoma, and how do treatment choices differ between BRAF-positive and BRAF-negative tumors?
Method: AI-assisted systematic review (Ralph Loop + Multi-Agent)
Report Version: 1.0
Executive Summary
Clinical Bottom Line
BRAF V600E mutation drives ~70% of ameloblastomas (predominantly mandibular, younger patients) and enables neoadjuvant BRAF/MEK inhibitor therapy that can convert radical resections to jaw-preserving surgery in >90% of cases — but BRAF-negative tumors (~30%, enriched in maxilla with SMO/KRAS/FGFR2 mutations) currently have no approved targeted therapy and remain surgical diseases.
Key Numbers
| Metric | Value | 95% CI / Source | GRADE |
|---|---|---|---|
| BRAF V600E pooled prevalence | 72.1% | 67.1–76.6% (Zhou 2026, N=2034) | +++○ |
| Neoadjuvant BRAF/MEKi radiologic response | 100% | Grynberg 2024, n=11 | ++○○ |
| Jaw preservation after neoadjuvant BRAF/MEKi | 91% | Grynberg 2024, n=11 | ++○○ |
| Conservative surgery recurrence (solid/multicystic) | 41% | vs 8% radical (Hendra 2019) | +++○ |
| Recurrence difference BRAF+ vs BRAF− | None significant | OR 0.93, p=0.78 (Martins-de-Barros 2023, N=855) | +++○ |
Main Findings
1. BRAF V600E in Ameloblastoma — Molecular Biology
Conclusion: BRAF V600E is the dominant oncogenic driver in ameloblastoma, activating MAPK/ERK signaling independently of upstream EGFR, and is likely an early pathogenic event.
Key data:
- Prevalence: 72.1% overall (Zhou 2026, 36 studies, N=2034); 65.3–70.5% in other meta-analyses
- By subtype: Unicystic ~80–96% (highest), conventional/solid ~63–84%, desmoplastic ~67%, adenoid 0% (CTNNB1-driven instead)
- By location: Mandible 78–84% BRAF+; maxilla ~0% (enriched for SMO instead)
- By age: Significantly associated with younger patients (<54 years); pediatric patients show excellent neoadjuvant response
- Posterior mandible: OR = 7.23 for BRAF positivity
- Mechanism: BRAF V600E → constitutive RAF kinase activation → MEK → ERK1/2 phosphorylation → cell proliferation, MMP2/MMP9-mediated invasion, Ki-67 upregulation; independent of EGFR signaling (PMID 38424736, 24993163)
Co-mutations (mutually exclusive with BRAF):
- SMO — maxillary predominance (~20–25% of all ameloblastomas)
- FGFR2 — activating mutations, mutually exclusive with RAS-BRAF
- KRAS/NRAS — part of FGFR2-RAS-BRAF axis covering 88% of cases (PMID 24993163)
- KMT2D — tumor suppressor co-mutations
- CTNNB1 — adenoid ameloblastoma (0% BRAF)
- PIK3CA — co-occurs with BRAF/SMO
Evidence: Multiple meta-analyses and large genomic studies (PMIDs 41980527, 37364158, 36428683, 24993163)
Clinical Implication: All ameloblastomas should undergo molecular profiling (at minimum BRAF V600E testing); mandibular tumors → test BRAF first; maxillary tumors → test SMO first.
2. BRAF-Positive Ameloblastoma: Targeted Therapy
Conclusion: BRAF/MEK inhibitor therapy (dabrafenib + trametinib preferred) produces near-universal tumor regression in BRAF V600E-positive ameloblastoma, with neoadjuvant use enabling jaw-preserving surgery in >90% of cases that would otherwise require radical resection.
Evidence:
| Study | Design | n | Regimen | Response | Key Outcome | GRADE |
|---|---|---|---|---|---|---|
| Grynberg 2024 (PMID 37966914) | Retrospective cohort | 11 | Dab ± Tram (neoadjuvant) | 100% radiologic | 91% jaw preservation; 1/11 recurrence at 14mo | ++○○ |
| Hirschhorn 2021 (PMID 34599642) | Prospective open-label | 3 (pediatric) | Dab + Tram | Complete regression | Ad integrum bone regeneration | +○○○ |
| Abramson 2022 (PMID 35447565) | Case report (8yr f/u) | 1 | Dab + Tram | Durable CR | Relapsed off-tx at 2.5yr; re-responded to rechallenge | +○○○ |
| Tan 2016 (PMID 27209484) | Case report | 1 | Dabrafenib | >90% volume reduction | Enabled less extensive surgery | +○○○ |
| Kaye 2015 (PMID 25475564) | Case report | 1 | Dab + Tram | Durable response (metastatic) | Sustained 4+ years | +○○○ |
| Broudic-Guibert 2019 (PMID 31340860) | Case report | 1 | Vemurafenib | PR (lung mets) | 28+ months | +○○○ |
| Büttner 2023 (PMID 38149213) | Case report | 1 | Dab + Tram (neoadjuvant) | 23% reduction; Ki67→0% | 18-month course | +○○○ |
| Raemy 2024 (PMID 38927880) | SR (13 studies) | 23 | MAPK inhibitors | 4 CR; near-universal response | — | ++○○ |
Preferred regimen: Dabrafenib + trametinib (dual BRAF/MEK blockade) over monotherapy, based on melanoma paradigm and emerging ameloblastoma data.
Safety: Predominantly grade 1–2 AEs (skin toxicity, fatigue, arthralgia, voice changes, dry eyes). Grade 3–4 uncommon (rash, hyperglycemia, AKI in Pediatric MATCH trial).
Clinical Implication: For BRAF V600E+ ameloblastoma, neoadjuvant dabrafenib + trametinib should be strongly considered before radical surgery — it may convert segmental mandibulectomy to curettage/enucleation.
3. BRAF-Negative Ameloblastoma: Surgical Management
Conclusion: Surgery remains the gold standard for BRAF-negative ameloblastoma. Conservative approaches have ~3× higher recurrence but lower morbidity; radical surgery has lower recurrence but 65% complication rate. BRAF status itself does NOT affect surgical recurrence risk.
Recurrence rates by approach:
| Subtype & Approach | Recurrence Rate | Source |
|---|---|---|
| Solid/multicystic — Conservative | ~41% | Hendra 2019 (PMID 30548549) |
| Solid/multicystic — Radical (resection) | ~8% | Hendra 2019 |
| Unicystic luminal — Enucleation + Carnoy’s | ~9–11% | Titinchi 2022 (PMID 34996630) |
| Unicystic mural — Resection | ~3% | Chaudhary 2024 (PMID 39181059) |
| Unicystic — Marsupialization → 2nd-stage | ~4.5% | Yang 2018 (PMID 29756338) |
| Desmoplastic | ~9.2% | Zheng 2025 (PMID 40364536) |
Adjuvant therapy:
- Carnoy’s solution reduces unicystic recurrence to ~9–11%
- Liquid nitrogen cryotherapy + curettage: 0–30% recurrence (pathologic fracture risk ~11% for lesions >4cm)
Long-term recurrence: 5-yr ~9–17%; 10-yr ~18–25%; 15-yr ~24%. Lifelong follow-up recommended.
QoL: Radical surgery — 65.6% complication rate (IAN paresthesia 20.3%, face asymmetry 17.2%); Conservative — lower morbidity, higher recurrence but manageable with close follow-up (PMID 33037802).
Clinical Implication: BRAF-negative ameloblastoma requires surgical treatment with subtype-stratified approach; conservative treatment with close follow-up is reasonable for unicystic luminal/intraluminal; resection preferred for solid/multicystic and mural unicystic.
4. BRAF+ vs BRAF−: Differential Treatment Strategy
Conclusion: BRAF V600E status fundamentally changes the treatment paradigm — BRAF+ tumors gain access to neoadjuvant targeted therapy that can avoid radical surgery, while BRAF− tumors are limited to surgery plus emerging (mostly preclinical) targeted options.
Decision framework (proposed, not yet guideline):
All ameloblastomas → Molecular profiling (BRAF, SMO, KRAS, FGFR2)
│
├── BRAF V600E+ (~70%, mandibular predominant)
│ │
│ ├── Neoadjuvant: Dabrafenib + Trametinib × 3–6 months
│ │ → 100% radiologic response expected
│ │ → Reassess surgical plan (often can downgrade)
│ │ → Jaw-preserving surgery in 91% of cases
│ │
│ └── Adjuvant: Consider continuation if incomplete resection
│
├── BRAF− / SMO+ (~20%, maxillary predominant)
│ │
│ ├── Surgery: Standard surgical approach (no targeted option yet)
│ │ ⚠️ Vismodegib INEFFECTIVE for SMO-L412F
│ │ → BMS-833923 or arsenic trioxide: preclinical only
│ │
│ └── Clinical trial referral for unresectable/recurrent
│
├── BRAF− / KRAS or NRAS+
│ └── MEK inhibitors: preclinical sensitivity; no clinical data
│
├── BRAF− / FGFR2+
│ └── Erdafitinib: 1 published case with 2+ year sustained response
│
└── BRAF− / other or unknown
└── Standard surgical approach per subtype
→ Genomic profiling for trial eligibility
Critical gaps:
- No RCT compares BRAF+ targeted therapy vs surgery (NCT06819605 Phase 2/3 RCT not yet recruiting)
- No guideline incorporates BRAF testing (WHO 2022 recognizes molecular characterization but doesn’t mandate it)
- Follow-up after neoadjuvant therapy is short (median 14 months in largest series)
- Optimal duration of neoadjuvant therapy undefined
- No data on whether BRAF+ patients who receive neoadjuvant therapy have equivalent long-term recurrence to upfront surgery
5. Emerging Therapies for BRAF-Negative Ameloblastoma
Conclusion: Several targeted approaches exist for BRAF− ameloblastoma based on alternative driver mutations, but clinical evidence is extremely limited.
| Target | Mutation | Drug | Evidence Level | Key Finding |
|---|---|---|---|---|
| SMO | L412F | Vismodegib | Preclinical — FAILED | Ineffective against SMO-L412F (PMID 35689405) |
| SMO | L412F | BMS-833923 | Preclinical | Reduces HH signaling + viability (PMID 35689405) |
| SMO | L412F | Arsenic trioxide | Preclinical | Inhibits SMO-L412F activity (PMID 24859340) |
| FGFR2 | V395D etc. | Erdafitinib | 1 clinical case | Sustained 2+ yr response (PMID 35761436) |
| KRAS/NRAS | Various | Trametinib/binimetinib | Preclinical | Exquisite sensitivity (PMID 35689405) |
| Circadian/BMAL1 | Vemurafenib resistance | GSK4112 + vemurafenib | Preclinical | Restores sensitivity (PMID 41349606) |
| EZH2 | Stemness-driven recurrence | EZH2 inhibitors | Preclinical | Eliminates CC stem cells in organoids (PMID 38424060) |
PRISMA Flow Diagram
Identification
├── Records from PubMed: 120+
├── Records from ClinicalTrials.gov: 4
├── Records from other web sources: 15+
│ Total identified: ~140
│
Screening
├── Duplicates removed: ~30
├── Records screened: ~110
├── Records excluded (off-topic): ~50
│
Eligibility
├── Full-text assessed: ~60
├── Full-text excluded: ~10
│ - Non-English: 3
│ - Conference abstracts only: 4
│ - Non-ameloblastoma: 3
│
Included
└── Studies in synthesis: ~50
Evidence Tables
Key Study Characteristics
| Study | Design | Setting | Population | n | Follow-up |
|---|---|---|---|---|---|
| Zhou 2026 (PMID 41980527) | SR/MA | 36 studies | All AM subtypes | 2034 | — |
| Martins-de-Barros 2023 (PMID 37364158) | SR/MA | 21 studies | All AM subtypes | 855 | — |
| Grynberg 2024 (PMID 37966914) | Retro cohort | Multicenter | BRAF+ AM | 11 | 14mo median |
| Hirschhorn 2021 (PMID 34599642) | Prospective | Single center | Pediatric BRAF+ AM | 3 | Variable |
| Bonacina 2022 (PMID 33827932) | Retro multicenter | 4 centers | BRAF+ vs BRAF− | 74 | — |
| Hendra 2019 (PMID 30548549) | SR/MA | 20 studies | Surgical outcomes | Variable | — |
| Brown 2014 (PMID 24993163) | Genomic | Single center | Molecular profiling | 84 | — |
| Nguyen 2022 (PMID 35689405) | Preclinical | 6 cell lines | SMO/RAS targeted | — | — |
| Lawson-Michod 2022 (PMID 35761436) | Case report | Single center | FGFR2+ AM | 1 | 2+ years |
Risk of Bias Assessment
Observational (Newcastle-Ottawa Scale):
- Grynberg 2024: Selection ★★★★ / Comparability ★★ / Outcome ★★ — 8/9 (High quality)
- Bonacina 2022: Selection ★★★ / Comparability ★★ / Outcome ★★ — 7/9 (High quality)
- Hendra 2019 (MA): High quality SR/MA
- Zhou 2026 (MA): High quality SR/MA, largest dataset
Case Reports/Series (JBI): Inherent selection bias; no comparator group. All case-level evidence rated LOW certainty.
Source Registry
Peer-Reviewed Articles
| PMID | First Author | Title | Journal | Year |
|---|---|---|---|---|
| 41980527 | Zhou | SR+MA of BRAF V600E in ameloblastoma | — | 2026 |
| 37966914 | Grynberg | Neoadjuvant dabrafenib±trametinib | J Natl Cancer Inst | 2024 |
| 37364158 | Martins-de-Barros | MA: BRAF V600E and recurrence | J Oral Pathol Med | 2023 |
| 37872712 | Singh | MA+metaregression: BRAF and recurrence | J Oral Pathol Med | 2023 |
| 35447565 | Abramson | 8-yr f/u BRAF/MEKi in AM | — | 2022 |
| 34599642 | Hirschhorn | Pediatric neoadjuvant BRAFi | — | 2021 |
| 35689405 | Nguyen | SMO-L412F vismodegib resistance; MEKi sensitivity | J Dent Res | 2022 |
| 35761436 | Lawson-Michod | Erdafitinib for FGFR2+ AM | Cancer Rep | 2022 |
| 38927880 | Raemy | SR: MAPK inhibitors in AM (23 pts) | Cancers | 2024 |
| 38693620 | Bologna-Molina | SR: BRAFi in AM (17 cases) | — | 2024 |
| 37115331 | Ebeling | SR: BRAFi responses (9 pts) | — | 2023 |
| 40898964 | Sulistyani | SR: BRAFi in AM (8 cases) | — | 2025 |
| 24993163 | Brown | Genomic profiling FGFR2-RAS-BRAF 88% | Clin Cancer Res | 2014 |
| 24859340 | Sweeney | SMO L412F discovery; ATO preclinical | Nat Genet | 2014 |
| 30548549 | Hendra | MA: conservative vs radical surgery | Oral Dis | 2019 |
| 33827932 | Bonacina | BRAF+ vs BRAF− surgical recurrence (n=74) | — | 2022 |
| 34998647 | Kunmongkolwut | BRAF and recurrence (n=74) | — | 2022 |
| 38424736 | Zhang | MAPK/ERK mechanism in AM | — | 2024 |
| 36625499 | Chang | BRAF as early event (IHC validation) | — | 2023 |
| 39274556 | Gasparro | Umbrella review: surgical outcomes | J Clin Med | 2024 |
| 33037802 | Hresko | Conservative vs radical QoL | Med Oral | 2021 |
| 31084977 | Au | Long-term recurrence (n=128) | Int J Oral Maxillofac Surg | 2019 |
| 34996630 | Titinchi | UA: enucleation + Carnoy’s | Br J Oral Maxillofac Surg | 2022 |
| 40364536 | Zheng | Desmoplastic AM (n=86+28) | Oral Dis | 2025 |
| 38424060 | Xiong | EZH2 targeting in AM organoids | Int J Oral Sci | 2024 |
| 41349606 | Li | Circadian clock + vemurafenib resistance | — | 2025 |
Clinical Trials
| NCT ID | Title | Phase | Status |
|---|---|---|---|
| NCT06819605 | Neoadjuvant Dab+Tram → Curettage vs Upfront Curettage (RCT) | 2/3 | NOT YET RECRUITING |
| NCT06653517 | Neoadjuvant BRAFV600E-Targeted Therapy for Conventional AM | 2 | RECRUITING |
| NCT06264778 | Fenestration Decompression + Dabrafenib for BRAF+ AM | 3 | UNKNOWN |
| NCT02367859 | Pilot: Dabrafenib+Trametinib for BRAF-Mutated AM | 2 | COMPLETED |
Verification Notes
- All PMIDs verified via PubMed e-utilities on 2026-05-17
- ClinicalTrials.gov data accessed via API on 2026-05-17
Limitations & Evidence Gaps
Methodological Limitations
- All clinical evidence for targeted therapy is case reports/series (highest n=11)
- No RCT data exists (first RCT not yet recruiting)
- Follow-up after neoadjuvant therapy is short (median 14 months)
- Selection bias inherent in published case reports (publication bias toward positive results)
- Heterogeneous treatment regimens (doses, duration, mono vs combo)
Evidence Gaps
- Long-term recurrence after neoadjuvant BRAF/MEKi — unknown if equivalent to surgery
- Optimal duration of neoadjuvant therapy — currently 3–20 months in published cases
- BRAF− targeted therapy — no clinical data beyond 1 FGFR2 case
- SMO inhibitor clinical trials — none registered despite preclinical promise
- BRAF testing as standard of care — no guideline mandates it yet
- Pediatric-specific protocols — limited to case reports
- Resistance mechanisms to BRAF/MEK inhibitors in ameloblastoma
Future Research Needs
- RCT: NCT06819605 (neoadjuvant Dab+Tram vs upfront surgery) — critical priority
- Clinical trial of BMS-833923 or arsenic trioxide for SMO-mutant ameloblastoma
- Prospective registry of BRAF/MEKi-treated ameloblastomas with long-term follow-up
- Biomarker-driven treatment algorithm validation study
Disclosures
Researcher: AI-assisted review, no human conflicts
AI Tool: Hermes (GLM-5.1 model) with ai-research-rounds skill (v2.0)
Funding: None
AI Research Rounds uses AI-assisted literature review to synthesize evidence on clinical questions. This report is for clinical decision support only — not a substitute for clinical judgment or institutional protocols.